Table 5. Regimen usage by line of treatment in non-TRD episodes.
| Line of treatment | ||||||||||
| Regimen | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 |
| SSRI only | 64% | 35% | 49% | 29% | 40% | 27% | 35% | 32% | 31% | 38% |
| Atypical ADs only | 12% | 8% | 12% | 9% | 12% | 7% | 12% | 12% | 12% | 8% |
| SNRI only | 10% | 9% | 13% | 8% | 12% | 9% | 11% | 3% | 14% | 8% |
| AD–Others only | 5% | 6% | 6% | 7% | 6% | 7% | 8% | 12% | 6% | 12% |
| SSRI & Other ADs | 3% | 10% | 6% | 13% | 10% | 17% | 14% | 11% | 8% | 15% |
| SSRI & Atypical AD | 2% | 12% | 4% | 13% | 5% | 12% | 6% | 4% | 8% | |
| SSRI & SNRI | 0% | 4% | 1% | 3% | 2% | 3% | 1% | 2% | ||
| SSRI & AP | 1% | 3% | 1% | 4% | 1% | 4% | 3% | 5% | 6% | 8% |
| N (Episodes) | 44,520 | 9,952 | 4,341 | 1,512 | 763 | 333 | 185 | 99 | 49 | 26 |
Note: ‘AD – Others’ includes alpha-2 receptor antagonists (tetracyclics), modified cyclics, tricyclic agents; Atypical AD includes miscellaneous antidepressants, chiefly bupropion;
AP (Antipsychotics) includes benzisoxazoles, butyrophenones, dibenzapines, dihydroindolones, phenothiazines, quinolinone derivatives, thioxanthenes.
Abbreviations: SSRI: Selective serotonin reuptake inhibitor;AD: Antidepressant; SNRI: Serotonin norepinephrine reuptake inhibitors.